ALAlicia N. Lyle

Alicia N. Lyle

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alicia N. Lyle has a total of 198 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessing Analytical Performance and Standardizing Lipid Measurements–Sometimes a Conundrum

    by Hubert W. Vesper, Uliana Danilenko, Otoe Sugahara, Sollip Kim, Yeo-Min Yun, Alicia N. Lyle

    Hubert W. Vesper, Ph.D., Uliana Danilenko, Ph.D., Otoe Sugahara, M.B.A., Sollip Kim, M.D., Ph.D., Yeo-Min Yun, M.D., Ph.D., and Alicia N. Lyle, Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2026.0111

  • Open Access

    Correlation and Commutability Study between an LC-MS-Based Reference Measurement Procedure and Immunoassays Measuring Apolipoprotein A-I and Apolipoprotein B

    by Ioannis Dikaios, Christa M Cobbaert, Vincent Delatour, Benjamin Dieplinger, Margot Egger, Chiara Giangrande, Roberta Girardi, Matthias Grimmler, Zhiyuan Li, Alicia N Lyle, et al.

    Background: Serum concentrations of apolipoprotein A-I (ApoA-I) and apolipoprotein B (ApoB) can have a predictive value for cardiovascular events beyond the traditional lipid profile. The IFCC Working Group on Apolipoproteins by Mass Spectrometry is developing a novel reference measurement system for seven clinically relevant apolipoproteins, including ApoA-I and ApoB. The system will consist of a multiplex mass spectrometry–based reference measurement procedure (RMP) and commutable secondary reference materials (RMs). Methods: Agreement between the RMP and 8 immunoassay-based measurement procedures (MPs) was investigated using 30 clinical samples. Furthermore, the commutability of 8 candidate RMs, consisting of frozen serum pools, and the existing WHO-IFCC standards SP1-01 and SP3-08 was assessed. Results: The harmonization level among eight immunoassay-based MPs for ApoA-I and ApoB still needs improvement. The RMP results showed a good correlation with results of the immunoassay-based MPs for both ApoA-I and ApoB. For ApoA-I, 7 candidate RMs showed good commutability, while SP1-01 and one candidate RM showed potential noncommutability for one method comparison. For ApoB, the commutability profile of the candidate RMs was more variable, and SP3-08 showed noncommutability for several method comparisons. Conclusions: The RMP and the immunoassay-based MPs have comparable selectivity for ApoA-I and ApoB, and a well-established reference measurement system can lead to improved harmonization. Future commutable secondary RMs can be based on frozen human serum pools; however, for ApoB, preselection of single-donor samples might be needed to limit the impact of sample-specific effects.

  • Open Access

    Highly specific ID-UHPLC-MS/MS method for analyzing polar and non-polar steroid hormones

    by Lumi Duke, Paul H. Kim, Alicia N. Lyle, Julianne C. Botelho, Natalie D. Shaw, Hubert W. Vesper

    The accurate and precise measurement of endogenous steroid hormone levels in serum is essential for their use as biomarkers of endocrine and metabolic diseases in patient care and translational science. Herein, we describe a newly developed, highly accurate, and precise isotope-dilution liquid chromatography-mass spectrometry (LC-MS/MS) method capable of simultaneously measuring eight clinically relevant polar and non-polar steroid hormones in 200 µL of serum. This steroid hormone panel method uses sequential liquid-liquid extractions for the isolation of total testosterone (TT), estradiol (E2), progesterone (P4), 17-hydroxyprogesterone (17-OHP), androstenedione (AD), estrone (E1), estrone sulfate (E1S), and dehydroepiandrosterone sulfate (DHEAS) without derivatization or hydrolysis. The method demonstrated a broad analytical measurement range for all eight hormones as a result of improved selectivity and sensitivity, making it suitable for the analysis of general population serum samples, including postmenopausal women and children. The total imprecision, expressed as coefficients of variation, was evaluated at three levels for each analyte and ranged from 3.5 to 10.7%. The mean bias to well-established secondary reference materials was −1.00% for TT and 1.91% for E2. When applied to 268 commercially sourced serum samples from men, women, and children, only 2% of measurement results were below the limits of detection; therefore, this method was deemed suitable for measurement of eight steroid hormones across the general population. The establishment of this new steroid hormone panel LC-MS/MS method will facilitate investigations of associations between health disorders and individualized steroid profiles, which can be utilized for evaluations at the individual or population levels.

  • Interlaboratory comparison of serum lipoprotein(a) analytical results across clinical assays—Steps toward standardization

    by Alicia N. Lyle, Elias N. Flores, Clark C. Coffman, Alex H. Doty, Otoe Sugahara, Florian Kronenberg, L. Renee Ruhaak, Christa M. Cobbaert, Hubert W. Vesper


  • Recommendations for Setting a Criterion and Assessing Commutability of Sample Materials Used in External Quality Assessment/Proficiency Testing Schemes

    by Sverre Sandberg, Pernille Fauskanger, Jesper V Johansen, Thomas Keller, Jeffrey Budd, Neil Greenberg, Robert Rej, Mauro Panteghini, Vincent Delatour, Ferruccio Ceriotti, et al.

    It is important for external quality assessment materials (EQAMs) to be commutable with clinical samples; i.e., they should behave like clinical samples when measured using end-user clinical laboratory in vitro diagnostic medical devices (IVD-MDs). Using commutable EQAMs makes it possible to evaluate metrological traceability and/or equivalence of results between IVD-MDs. The criterion for assessing commutability of an EQAM between 2 IVD-MDs is that its result should be within the prediction interval limits based on the statistical distribution of the clinical sample results from the 2 IVD-MDs being compared. The width of the prediction interval is, among other things, dependent on the analytical performance characteristics of the IVD-MDs. A presupposition for using this criterion is that the differences in nonselectivity between the 2 IVD-MDs being compared are acceptable. An acceptable difference in nonselectivity should be small relative to the analytical performance specifications used in the external quality assessment scheme. The acceptable difference in nonselectivity is used to modify the prediction interval criterion for commutability assessment. The present report provides recommendations on how to establish a criterion for acceptable commutability for EQAMS, establish the difference in nonselectivity that can be accepted between IVD-MDs, and perform a commutability assessment. The report also contains examples for performing a commutability assessment of EQAMs.


  • Recommendations for Setting a Criterion for Assessing Commutability of Secondary Calibrator Certified Reference Materials

    by W Greg Miller, Thomas Keller, Jeffrey Budd, Jesper V Johansen, Mauro Panteghini, Neil Greenberg, Vincent Delatour, Ferruccio Ceriotti, Liesbet Deprez, Robert Rej, et al.

    A secondary higher-order calibrator is required to be commutable with clinical samples to be suitable for use in the calibration hierarchy of an end-user clinical laboratory in vitro diagnostic medical device (IVD-MD). Commutability is a property of a reference material that means results for a reference material and for clinical samples have the same numeric relationship, within specified limits, across the measurement procedures for which the reference material is intended to be used. Procedures for assessing commutability have been described in the literature. This report provides recommendations for establishing a quantitative criterion to assess the commutability of a certified reference material (CRM). The criterion is the maximum allowable noncommutability bias (MANCB) that allows a CRM to be used as a calibrator in a calibration hierarchy for an IVD-MD without exceeding the maximum allowable combined standard uncertainty for a clinical sample result (umaxCS). Consequently, the MANCB is derived as a fraction of the umaxCS for the measurand. The suitability of an MANCB for practical use in a commutability assessment is determined by estimating the number of measurements of clinical samples and CRMs required based on the precision performance and nonselectivity for the measurand of the measurement procedures in the assessment. Guidance is also provided for evaluating indeterminate commutability conclusions and how to report results of a commutability assessment.


  • Open Access

    Assessment of WHO 07/202 reference material and human serum pools for commutability and for the potential to reduce variability among soluble transferrin receptor assays

    by Alicia N. Lyle, Jeffrey R. Budd, Victoria M. Kennerley, Bianca N. Smith, Uliana Danilenko, Christine M. Pfeiffer, Hubert W. Vesper

    Objectives: The clinical use of soluble transferrin receptor (sTfR) as an iron status indicator is hindered by a lack of assay standardization and common reference ranges and decision thresholds. In 2009, the WHO and National Institute for Biological Standards and Controls (NIBSC) released a sTfR reference material (RM), 07/202, for assay standardization; however, a comprehensive, formal commutability study was not conducted. Methods: This study evaluated the commutability of WHO 07/202 sTfR RM and human serum pools and the impacts of their use as common calibrators. Commutability was assessed for six different measurement procedures (MPs). Serum pools were prepared according to updated CLSI C37-A procedures (C37) or non-C37 procedures. The study design and analyses were based on Parts 2 and 3 of the 2018 IFCC Commutability in Metrological Traceability Working Group’s Recommendations for Commutability Assessment. WHO 07/202 and serum pools were used for instrument/assay and mathematical recalibration, respectively, to determine if their use decreases inter-assay measurement variability for clinical samples. Results: The WHO 07/202 RM dilutions were commutable for all 6 MPs assessed and, when used for instrument calibration, decreased inter-assay variability from 208 to 55.7 %. Non-C37 and C37 serum pools were commutable for all 6 MPs assessed and decreased inter-assay variability from 208 to 13.8 % and 4.6 %, respectively, when used for mathematical recalibration. Conclusions: All materials evaluated, when used as common calibrators, substantially decreased inter-assay sTfR measurement variability. MP calibration to non-C37 and C37 serum pools may reduce the sTfR IMPBR to a greater extent than WHO 07/202 RM.


  • Open Access

    Development of an LC-MRM-MS-Based Candidate Reference Measurement Procedure for Standardization of Serum Apolipoprotein (a) Tests

    by L Renee Ruhaak, Fred P H T M Romijn, Ilijana Begcevic Brkovic, Zsusanna Kuklenyik, Julia Dittrich, Uta Ceglarek, Andrew N Hoofnagle, Harald Althaus, Eduardo Angles-Cano, Stefan Coassin, et al.

    Background: Medical results generated by European CE Marking for In Vitro Diagnostic or in-house tests should be traceable to higher order reference measurement systems (RMS), such as International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)-endorsed reference measurement procedures (RMPs) and reference materials. Currently, serum apolipoprotein (a) [apo(a)] is recognized as a novel risk factor for cardiovascular risk assessment and patient management. The former RMS for serum apo(a) is no longer available; consequently, an International System of Units (SI)-traceable, ideally multiplexed, and sustainable RMS for apo(a) is needed.Methods: A mass spectrometry (MS)-based candidate RMP (cRMP) for apo(a) was developed using quantitative bottom-up proteomics targeting 3 proteotypic peptides. The method was provisionally validated according to ISO 15193 using a single human serum based calibrator traceable to the former WHO-IFCC RMS.Results: The quantitation of serum apo(a) was by design independent of its size polymorphism, was linear from 3.8 to 456 nmol/L, and had a lower limit of quantitation for apo(a) of 3.8 nmol/L using peptide LFLEPTQADIALLK. Interpeptide agreement showed Pearson Rs of 0.987 and 0.984 for peptides GISSTVTGR and TPENYPNAGLTR, and method comparison indicated good correspondence (slopes 0.977, 1.033, and 1.085 for LFLEPTQADIALLK, GISSTVTGR, and TPENYPNAGLTR). Average within-laboratory imprecision of the cRMP was 8.9%, 11.9%, and 12.8% for the 3 peptides.Conclusions: A robust, antibody-independent, MS-based cRMP was developed as higher order RMP and an essential part of the apo(a) traceability chain and future RMS. The cRMP fulfils predefined analytical performance specifications, making it a promising RMP candidate in an SI-traceable MS-based RMS for apo(a).


  • Open Access

    Commutability Assessment of Candidate Reference Materials for Lipoprotein(a) by Comparison of a MS-based Candidate Reference Measurement Procedure with Immunoassays

    by Ioannis Dikaios, Harald Althaus, Eduardo Angles-Cano, Uta Ceglarek, Stefan Coassin, Christa M Cobbaert, Vincent Delatour, Benjamin Dieplinger, Matthias Grimmler, Andrew N Hoofnagle, et al.

    Background: Elevated concentrations of lipoprotein(a) [Lp(a)] are directly related to an increased risk of cardiovascular diseases, making it a relevant biomarker for clinical risk assessment. However, the lack of global standardization of current Lp(a) measurement procedures (MPs) leads to inconsistent patient care. The International Federation for Clinical Chemistry and Laboratory Medicine working group on quantitating apolipoproteins by mass spectrometry (MS) aims to develop a next-generation SI (International system of units)-traceable reference measurement system consisting of a MS-based, peptide-calibrated reference measurement procedure (RMP) and secondary serum-based reference materials (RMs) certified for their apolipoprotein(a) [apo(a)] content. To reach measurement standardization through this new measurement system, 2 essential requirements need to be fulfilled: a sufficient correlation among the MPs and appropriate commutability of future serum-based RMs.Methods: The correlation among the candidate RMP (cRMP) and immunoassay-based MPs was assessed by measuring a panel of 39 clinical samples (CS). In addition, the commutability of 14 different candidate RMs was investigated.Results: Results of the immunoassay-based MPs and the cRMPs demonstrated good linear correlations for the CS but some significant sample-specific differences were also observed. The results of the commutability study show that RMs based on unspiked human serum pools can be commutable with CS, whereas human pools spiked with recombinant apo(a) show different behavior compared to CS.Conclusions: The results of this study show that unspiked human serum pools are the preferred candidate secondary RMs in the future SI-traceable Lp(a) Reference Measurement System.